Born and raised in Christchurch, New Zealand, Dr. Ian Bathurst completed his studies in the UK, obtaining a PhD in Biochemistry from the University of London. He then pursued a successful career in academia at the University of Otago, New Zealand.
In 1986, he decided to change tack and moved to San Francisco to work at Chiron Corporation on the expression of yeast recombinant proteins, HIV genes, and potential vaccine candidates. Always a pioneer, he continued this work through two start-up companies, LXR Biotechnology Inc. and Arriva Pharmaceuticals Inc.
Ian brought this wealth of academic and industry experience to the MMV team when he joined as Director of Drug Discovery in 2004. As one of the first members of the Drug Discovery team, he was instrumental in helping to establish MMV’s networks and early-stage projects. He was continually seeking novel ways to facilitate the production of antimalarials and was an active member of the Artemisinin Enterprise that sought to optimize the production and extraction of artemisinin.
Ian was an invaluable member of the MMV team and a much respected mentor to the discovery team. He was planning an active retirement in 2011, when he passed away. He would be delighted that young researchers in malaria and neglected diseases were receiving support to attend the Keystone Symposia conference in his name.